Triton Partners is said to be considering making a bid to acquire Evotec SE, a German drug developer, after becoming one of its largest shareholders.
The private equity firm has been actively seeking meetings with top executives at Evotec as it assesses the possibility of a buyout.
Recent regulatory filings show that Triton has increased its stake in Evotec to 9.99% through a series of transactions. This move positions Triton as a significant player in the company's shareholder landscape, potentially opening the door for a strategic acquisition.